Palatin ploughs barren female sexual dysfunction field
This article was originally published in Scrip
Executive Summary
New Jersey's Palatin Technologies has initiated a pivotal Phase III trial for its female sexual dysfunction (FSD) drug bremelanotide, ploughing ahead in what appears to be a difficult area. Companies which have attempted to till this field have typically found their crops lacking, and Palatin itself is no stranger to the FSD drought.